As criticism of pharmacy benefit managers intensifies, CVS Caremark (CVS) plans to roll out a new prescription-drug pricing model next month for health plans that the company maintains will “simplify” costs and simultaneously add a dose of transparency to a highly opaque system.

In short, the PBM will offer so-called guaranteed net pricing for average prescription claims, whether medicines are purchased by mail or from retail or specialty pharmacies. CVS says it will pass through all rebates and administrative fees to its clients while assuming responsibility for manufacturer price hikes and shifts in the mix of brand and generic drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy